The above observations clearly indicate that SPHK1 exhibit a good diagnostic ability in differentiating the lymph node metastasis and TNM stages and might serve as a potential biomarker to predict the clinical outcome in breast cancer patients. Here, SPHK1 is linked to metastatic malignant neoplasm in the lymph nodes.